Patients with type 2 diabetes mellitus with hypertension
Conditions
Interventions
After completion of valsaltan 80 mg/day run in the period, the participants were randomized into one of two treatment groups
the 20 mg/day azilsartan group (A group) instead of valsaltan. After 16 weeks of azilsartan , the subjects in A group were switched to valsartan 80mg/day in the washout period for 16 weeks. subject i
the 20 mg/day olmesartan (O group) instead of valsaltan. After 16 weeks of olmesrtan treatment, the subjects in O group were switched to valsartan 80mg/day in the washout period for 16 weeks. subject
Sponsors
Juntendo University Graduate School of Medicine,Department of Metabolism & Endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 Diabetes mellitus 2)Hypertension (130/80mmHg) 3)Patients treated with varsartan 80mg/day
Exclusion criteria
Exclusion criteria: 1)Pregnant, lactating, and possibly pregnant women 2)severe liver disease 3)severe kidney disease(s-Cr 2.0mg/dl and mora) 4) Treatment with insurin 5) patients who have allergy to the medicine used in this study 6)Patients attending physician has determined is inappropriate for research participation 7)Patients who do not obtain written consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Office blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| 24hour blood pressure,daytime blood pressure,night time blood pressure(ABPM at 16,48weeks),HbA1c, FBG, IRI, urinary microalbumin, glucosylated albumin, hs-CRP, adiponectin, L-FABP, pentraxin3 | — |
Countries
Japan
Contacts
Public ContactMasaki Miura
Juntendo University Faculty of Medicine Department of metabolism and endocrinology
Outcome results
None listed